Accelerating CRB1 Research: Eye on the Finish Line

On November 29, 2021 the Curing Retinal Blindness Foundation, the global patient organization for CRB1 inherited retinal disease, produced a live event to inform the CRB1 and greater IRD community of the progress and potential for CRB1 disease research and to initiate a call to action for people and organizations to get involved in fundraising, with an initial goal of $3 Million by May 2022 to fund multiple projects that will lead to clinical trials for CRB1 LCA/RP (see speaker schedule below) To DONATE to this mission to FUND THE FINISH LINES for CRB1 go to www.crb1.org/donate To discuss a major contribution/collaboration, please email Kristin Smedley, CRBF CEO, at [email protected] Accelerating CRB1 Treatments: Eye on the Finish Line Monday, 11/29 10:00am-11:00am (Eastern US)  Part 1: Welcome & Purpose Kristin Smedley CEO, Curing Retinal Blindness Foundation Part 2: State of CRB1 Research: Where We Are and Where We Are Heading Irene Maumenee Director, Applied Genetics Columbia University Part 3: What is CRISPR and Experiments with CRISPR in Ophthalmology Fyodor Urnov Professor, Molecular and Cell Biology Department Scientific Director, Technology and Translation, Innovative Genomics Institute  Part 4: How can CRISPR work for CRB1 Peter Quinn Department of Ophthalmology Columbia University, Edward S. Harkness Eye Institute Part 5: Multiple Approaches to Studying CRB1 Marius Ueffing Chairman & Director, Institute for Ophthalmic Research Head, Department for Ophthalmology, Medical Bioanalytics Centre Tübingen University of Tübingen Part 6: Financial & Professional Commitments to Achieve Finish Lines Kristin Smedley Part 7: Important Role of CRB1 Families & Professionals Meghan  DeBenedictis Licensed, Certified Genetic Counselor Clinical Professor of Ophthalmology Director, Genetics Business Development Cleveland Clinic Part 8: Call to Action